A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
Clinical trial NCT06060457 · COMPLETED
Trial details
- NCT number
- NCT06060457
- Sponsor
- ModernaTX, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-25
- Primary completion
- 2024-06-07
- Enrollment
- 1900
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.